EMPOWUR enrolled 1518 patients across 199 sites, including 547 patients (36.0%) treated with vibegron, 540 (35.6%) receiving placebo, and 431 (28.4%) receiving tolterodine. Treatment groups were well-balanced with mean patient ages of ~60 years; each group included ~85% women and ~77% with OAB wet. The adjusted proportion of patients achieving a clinically meaningful (≥75%) reduction in UUI episodes/day (UUI responders) was highest for vibegron (49.3%), compared with placebo (32.8%) (P<0.0001) and tolterodine (42.2%) at week 12 (Figure 1). Vibegron demonstrated rapid onset of effect, with statistically significantly more UUI responders by week 2 vs placebo (P<0.01). For average volume (mL) voided per micturition, the placebo-adjusted mean change from baseline was significantly improved (increased) at week 12 with vibegron by 21.2 mL (standard deviation [SD], 3.52; P<0.0001 vs placebo), which was numerically greater than with tolterodine, 13.3 mL (SD, 3.76; P<0.001 vs placebo) (Figure 2). The least-squares mean change from baseline for total daily incontinence was reduced by 2.3 episodes in the vibegron group at 12 weeks (Figure 2). Placebo-adjusted mean total daily incontinence episodes were significantly reduced at week 12 with vibegron, by -0.7 episodes (standard error [SE], 0.16; P<0.0001 vs placebo), which was numerically greater than the reduction with tolterodine, -0.5 episodes (SE, 0.17; P=0.0074 vs placebo) (Figure 2). Rapid and statistically significant improvement in total daily incontinence was observed at week 2 (-0.7, placebo-adjusted) with vibegron and maintained statistical significance through week 12. Vibegron demonstrated statistically significant improvements on the Symptom Bother (P<0.0001), Concern (P<0.0001), Sleep (P<0.001), and Coping (P=0.0038) scales and total HRQL score (P<0.001) vs placebo at week 12 (Figure 2). The least-squares mean difference between vibegron and placebo was numerically improved for the HRQL Social Interaction subscale but did not reach statistical significance (P=0.1116). Vibegron results were numerically better than tolterodine results for all OAB-q LF scales measured (Figure 2). The most common adverse events (> placebo and >2%) were headache (vibegron, 4.0%; placebo, 2.4%; tolterodine, 2.6%), nasopharyngitis (vibegron, 2.8%; placebo, 1.7%; tolterodine, 2.6%), diarrhea (vibegron, 2.2%; placebo, 1.1%; tolterodine, 2.1%), and nausea (vibegron, 2.2%; placebo, 1.1%; tolterodine, 1.2%). Notably, hypertension was 1.7% for vibegron and placebo, and 2.6% for tolterodine.